Progressive structural bone changes and their relationship with treatment in patients with psoriatic arthritis: a longitudinal HR-pQCT study

Table 3 Number of lesions with progression and the change in volume of the lesions over 5 years

	SDL group (n = 26)	Non-SDL group (n = 34)	P value	TNFi group (n = 14)	Non-TNFi group (n = 46)	P value
Erosions, N (%)
Progression	12/51 (23.5)	25/60 (41.7)	0.043	8/26 (30.8)	29/85 (34.1)	0.751
Non-progression	39/51 (76.5)	35/60 (58.3)	0.043	18/26 (69.2)	56/85 (65.9)	0.751
Enthesiophytes, N (%)
Progression	17/40 (42.5)	33/59 (55.9)	0.190	15/29 (51.7)	36/70 (51.4)	0.979
Non-progression	23/40 (57.5)	26/59 (44.1)	0.190	14/29 (48.3)	34/70 (48.6)	0.979
Mean change of volume
Erosions (mm³)	0.5 ± 1.6	0.7 ± 1.4	0.100	0.3 ± 1.2	0.7 ± 1.6	0.638
Enthesiophytes (mm³)	0.3 ± 0.7	0.6 ± 0.8	0.048	0.4 ± 0.7	0.5 ± 0.8	0.620

Results are mean ± SD or number (percentage). Significant results are highlighted in italics
SDL group achieved sustained DAPSA-LDA, non-SDL group did not achieve sustained DAPSA-LDA, TNFi group patients who received TNF inhibitor throughout 5 years, non-TNFi group patients who did not receive TNF inhibitor throughout 5 years

ISSN: 1478-6362